Veeva insider sale disclosures show Senior Vice President, General Counsel and Secretary Jonathan Faddis sold 5,198 shares on October 14, 2026, leaving him with 4,130 shares. The transaction reduced his reported direct holding by approximately 55.7%, while leaving him with a continuing stake in the life-sciences software company.
Key Takeaways
- Faddis retained about 44.3% of his implied pre-sale direct holding.
- The SEC ownership disclosure was filed on October 16, two days after the transaction.
- The available information does not establish his reason for selling or a confirmed execution price.
Table of Contents
- Veeva insider sale cuts Faddis’s direct holding
- Selling history does not establish a motive
- Conclusion
Veeva insider sale cuts Faddis’s direct holding
Adding the 5,198 shares sold to the 4,130 shares remaining gives an implied pre-sale direct holding of 9,328 shares. The sale therefore represented more than half of that position, rather than a complete exit.
The SEC’s October 16 Form 4 filing record identifies Veeva Systems as the issuer and Jonathan Faddis as the reporting person, with October 14, 2026, listed as the reporting period. This separates the ownership-change date from the date the disclosure was submitted.
The filing-detail page confirms those identities and dates but does not display the underlying transaction table. It therefore does not independently verify the reported share quantities or establish the price received.
| Item | Details |
|---|---|
| Stock ticker | VEEV |
| Disclosure type | Form 4 statement of changes in beneficial ownership |
| Faddis shares sold over the preceding year | 5,198 |
| Faddis shares purchased over the preceding year | 0 |
Selling history does not establish a motive
The supplied transaction history lists 11 insider sales and no insider purchases at Veeva over the preceding year. These are transaction counts, not a measure of the total value sold or evidence of a shared view among executives.
The available information does not identify why Faddis sold or whether the transaction followed a prearranged trading plan. The size of the reduction alone cannot establish his assessment of Veeva’s prospects.
Veeva provides cloud-based software for pharmaceutical, biotechnology and medical-device companies, covering commercial, clinical, regulatory and quality operations. This transaction concerns an executive’s personal shareholding, not newly issued stock raising capital for the business.
Conclusion
Faddis’s reported sale substantially reduced his direct holding without eliminating it. The underlying transaction table remains the next detail to check for execution terms; the filing index alone does not resolve them.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
